Esophagectomy in patients with esophageal squamous cell carcinoma and distant nodal metastasis

Abstract

Summary The role of surgery in oligometastatic esophageal squamous cell carcinoma (ESCC) remains controversial. This study evaluated the oncological outcomes after esophagectomy in patients with ESCC with distant lymph node (LN) metastasis. Patients with ESCC and nodal metastasis treated with chemoradiotherapy or chemotherapy followed by esophagectomy between 2010 and 2020 were included. Overall survival (OS) and recurrence-free survival (RFS) were compared between patients with distant LN metastasis (dLN+) and exclusively regional LN metastasis (dLN–). The cohort comprised 69 dLN+ and 111 dLN– patients. Survival was significantly better in the dLN– group than in the dLN+ group (5-year OS, 51.9% vs. 25.5%, P < 0.001; RFS, 47.2% vs. 18.1%, P < 0.001). Stratified by the yp stage, 49 (44.1%) dLN– and 30 (43.5%) dLN+ patients achieved a pathological complete response (pCR). In the dLN– and dLN+ groups, the OS rates were significantly higher in the pCR group than in the non-pCR group (dLN–: 76.7% vs. 32.4%, P < 0.001; dLN+: 39.6% vs. 14.2%; P = 0.002). The dLN–/pCR group had the best OS, significantly outperforming the dLN−/non-pCR and dLN+/pCR groups. OS did not differ between the dLN−/non-pCR and dLN+/pCR groups. The dLN+/non-pCR group had the worst OS. The RFS analysis paralleled the OS findings. Patients with dLN+ disease had worse outcomes than their dLN– counterparts, irrespective of the pCR status. The survival rates were poor but comparable between the dLN+/pCR and dLN−/non-pCR groups. Adjuvant therapy may be required for dLN+ patients following systemic treatment and surgery, even after achieving pCR.